Stock comparison
Abbott Laboratories
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABT
Abbott Laboratories
Market cap
$152.25B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABT | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 61C | 70B | HAE |
| Benjamin Graham | 69B | 85A | HAE |
| Philip Fisher | 46D | 60C | HAE |
| Peter Lynch | 24F | 54C | HAE |
| Joel Greenblatt | 42D | 31F | ABT |
| Charlie Munger | 57C | 54D | ABT |
| Terry Smith | 54D | 55D | HAE |
Side-by-side metrics
| Metric | ABT | HAE |
|---|---|---|
| Market cap | $152.25B | $2.98B |
| P/E (TTM) | 23.5x | 24.8x |
| EV/EBIT | 21.7x | 14.1x |
| ROIC (TTM) | 6.56% | 8.37% |
| Gross margin | 56.38% | 55.74% |
| Net margin | 13.91% | 7.29% |
| Revenue CAGR 5y | 0.72% | 7.65% |
| EPS CAGR 5y | -1.48% | 24.62% |
| Debt / Equity | 0.7x | 1.5x |
| Dividend yield | 2.89% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABT leads on
- Dividend yield2.89%vs 0.0%+100%
- Market cap$152.25Bvs $2.98B+98%
- Debt / Equity0.7xvs 1.5x+57%
- Net margin13.91%vs 7.29%+48%
HAE leads on
- EPS CAGR 5y24.62%vs -1.48%+106%
- Revenue CAGR 5y7.65%vs 0.72%+91%
- EV/EBIT14.1xvs 21.7x+35%
- ROIC (TTM)8.37%vs 6.56%+22%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.